Ascorbic acid treatment for progressive bone metastases after radiotherapy A pilot study
Yazarlar (8)
Hüriye Şenay Kızıltan
Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Doç. Dr. Ayşe GÜNEŞ BAYIR Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Murat Demirtaş
Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
İsmail Meral
Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Özgür Taşpınar
Ali Hikmet Eriş
Prof. Dr. Teoman Aydın Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Prof. Dr. Alpaslan Mayadağlı Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE (Q4) | ||
| Dergi ISSN | 1078-6791 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 01-2014 |
| Cilt / Sayı / Sayfa | 20 / 2 / 16–20 | DOI | – |
| UAK Araştırma Alanları |
Veteriner Gıda Hijyeni ve Teknolojisi
|
||
| Özet |
| Context • Researchers have reported improved survival rates for patients with cancer when 10-75 g of vitamin C (ascorbic acid, or AA) is administered intravenously. AA exhibits a cytotoxic effect upon entering a cancer cell. Objective • The current study examined the benefits of intravenous administration of AA in treatment of bone metastases. Design • The study was a pilot study. Setting • The study was performed at Bezmialem Vakif University Medical Facility (BVUMF) in the Department of Radiation Oncology, from 2010-2012. Participants • Participants were 11 cancer patients with bone metastases who were unresponsive to standard cancer treatments and who experienced the following issues after receiving a total of 3000 cGy of radiotherapy: (1) intensifying pain, (2) an increase in metastatic sites, and/or (3) a deterioration in general health. Intervention • The 11 patients received 2.5 g of AA in a physiological saline solution, within 1 h period with 3-10 applications following at 1-wk intervals. Outcome Measures • The ECOG Performance Scale and Visual Analog Scale were used to assess performance and pain. Results • Among the participants administered AA, the mean reduction in pain was 55%, and the median survival time was 10 mo. Participants experienced a 40% grade-I gastrointestinal toxicity and a 30% urinary toxicity. Conclusions • Given the study's results, the current research team found considerable encouragement in the use of AA after radiotherapy for treatment of patients with bone metastases. Toxicity was in the acceptable range for AA treatment. |
| Anahtar Kelimeler |
